Retatrutide

What it is

Retatrutide is an investigational metabolic drug being developed by Eli Lilly and Company. It belongs to the newer class of multi-receptor incretin agonists, but differs from currently approved GLP-1 or GIP/GLP-1 drugs because it activates three receptors: GIP, GLP-1, and glucagon^{[4 ]}. The compound was described in a 2022 Cell Metabolism publication as LY3437943, a triple-agonist peptide designed for glycemic control, body-weight reduction, and metabolic effects^{[4 ]}.

Biological rationale

The rationale for combining these pathways is biological rather than cosmetic. GLP-1 receptor activation is associated with increased satiety, delayed gastric emptying, and glucose-dependent insulin effects. GIP receptor activity may contribute to insulin secretion and metabolic signaling. Glucagon receptor activation is more complex: glucagon can raise glucose in some contexts, but pharmacologic glucagon receptor agonism may also increase energy expenditure and affect hepatic lipid metabolism^{[4 ]}. Retatrutide’s development program is testing whether the combined effect of these pathways can produce clinically meaningful weight, glycemic, and liver-fat outcomes.

Identity

FDA’s Substance Registration System lists retatrutide under UNII NOP2Y096GV, with synonyms including LY3437943 and LY-3437943; PubChem lists the molecular formula as C₂₂₁H₃₄₂N₄₆O₆₈ and molecular weight of approximately 4,731 g/mol^{[1 –2 ]}.

Administration in trials

Retatrutide is administered by subcutaneous injection in clinical trials. This is descriptive, not a dosing recommendation. There is no FDA-approved retatrutide label, no approved dose, and no approved prescribing information^{[3 ]}. Lilly describes retatrutide as an investigational once-weekly triple hormone receptor agonist and states that it is legally available only to participants in Lilly clinical trials^{[5 ]}.

Online “retatrutide” is a separate problem

Public interest in retatrutide has accelerated because early and topline trials have reported large mean weight reductions. That public interest has also created an unregulated market for products sold online as “retatrutide,” “reta,” or “Triple G.” FDA has warned that retatrutide and cagrilintide cannot be used in compounding under federal law and has issued warning letters to companies selling products marketed as retatrutide^{[3 ,6 ]}.

Regulatory status

Retatrutide is investigational in the United States. It is not FDA-approved for obesity, type 2 diabetes, MASLD, knee osteoarthritis, obstructive sleep apnea, or any other indication^{[3 ,5 ]}. There is no FDA-approved retatrutide prescribing information, no approved commercial product, and no lawful routine prescribing pathway outside clinical trials.

Compounding is not allowed

FDA’s current GLP-1 safety page states specifically that retatrutide and cagrilintide cannot be used in compounding under federal law, are not components of FDA-approved drugs, and have not been found safe and effective for any condition^{[3 ]}. That point is important because some online marketing uses the word “compounded” to imply legality or pharmacy oversight. Under FDA’s framework, compounded drugs are not FDA-approved, and bulk drug substances used in compounding must fit the statutory conditions for 503A or 503B compounding^{[3 ,7 ]}.

Enforcement actions

FDA has also taken enforcement action against vendors selling products marketed as retatrutide. In a March 31, 2026 warning letter to Gram Peptides, FDA stated that the firm offered “Retatrutide” for sale in the United States and that the products were unapproved new drugs; FDA also emphasized the special safety concern with injectable products because they bypass some of the body’s defenses against toxins and microorganisms^{[6 ]}.

Controlled-substance status

Retatrutide is not a DEA-scheduled controlled substance under the federal controlled-substance schedules reviewed for this draft, but lack of DEA scheduling does not make an unapproved drug lawful to sell, compound, prescribe, or use outside an investigational pathway. The operative regulatory issue is FDA drug approval and compounding law, not controlled-substance scheduling.

Internationally, no approval by a major regulator was confirmed for this draft. Lilly’s phase 3 programs are ongoing or have recently read out topline results, but topline results and clinical-trial registration do not equal approval. Last regulatory verification: May 5, 2026.

Research summary

The first major public scientific foundation for retatrutide was the 2022 Cell Metabolism paper by Coskun and colleagues. That publication described LY3437943 as a triple agonist peptide at glucagon, GIP, and GLP-1 receptors. In vitro and animal data suggested effects on body weight and glycemic control, and a phase 1 single-ascending-dose study supported once-weekly clinical development. The authors reported a safety and tolerability profile similar to other incretin-based drugs in early human testing^{[4 ]}. All authors were Eli Lilly employees or stockholders, which should be considered when interpreting early development data.

Phase 2 — obesity (Jastreboff 2023)

In adults with obesity or overweight without diabetes, Jastreboff and colleagues published a phase 2 randomized, double-blind, placebo-controlled trial in the New England Journal of Medicine in 2023. The trial randomized 338 adults to once-weekly retatrutide dose groups or placebo for 48 weeks. Lilly’s release summarizing the peer-reviewed publication reported mean weight reduction up to 17.5% at 24 weeks and up to 24.2% at 48 weeks in a secondary endpoint^{[8 ]}. These results made retatrutide one of the most closely watched investigational obesity drugs, but phase 2 trials are not sufficient for approval.

Phase 2 — type 2 diabetes (Rosenstock 2023)

A separate phase 2 randomized, double-blind, placebo- and active-controlled trial in adults with type 2 diabetes was published in The Lancet in 2023. Rosenstock and colleagues enrolled adults with type 2 diabetes, HbA1c 7.0–10.5%, and BMI 25–50 kg/m². The study examined retatrutide across a range of doses and included placebo and dulaglutide comparator arms^{[9 ]}. Secondary summaries of that trial note large reductions in HbA1c and body weight, but the clinical meaning depends on full dose group, comparator, estimand, and adverse-event interpretation. As with the obesity phase 2 trial, this was investigational research rather than approved treatment evidence.

MASLD substudy (Sanyal 2024)

A MASLD substudy published in Nature Medicine in 2024 evaluated participants from the phase 2 obesity study who had at least 10% liver fat by MRI-PDFF. In 98 participants, mean relative liver-fat change at 24 weeks was −42.9%, −57.0%, −81.4%, and −82.4% across retatrutide 1, 4, 8, and 12 mg groups, versus +0.3% with placebo^{[10 ]}. At week 24, liver fat below 5% was achieved by 27%, 52%, 79%, and 86% of participants in the retatrutide groups, versus 0% with placebo^{[10 ]}. These results are notable, but the substudy was small, selected from a larger obesity trial, and used imaging endpoints rather than hard liver outcomes such as fibrosis progression, cirrhosis, or transplant-free survival.

Phase 3 topline — TRIUMPH-4 (December 2025)

In December 2025, Lilly announced topline phase 3 TRIUMPH-4 results in adults with obesity or overweight and knee osteoarthritis, without diabetes. The trial randomized 445 participants and reported that the 12 mg retatrutide arm lost an average of 28.7% body weight at 68 weeks using the efficacy estimand, compared with 2.1% for placebo. Lilly also reported WOMAC pain-score reductions and physical-function improvements^{[11 ]}. These results had not yet been published in a peer-reviewed journal as of this draft, so they should be treated as company-reported topline data.

Phase 3 topline — TRANSCEND-T2D-1 (March 2026)

In March 2026, Lilly announced topline phase 3 TRANSCEND-T2D-1 results in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone. Lilly reported average A1c reductions of 1.7% to 2.0% across retatrutide groups at 40 weeks and average body-weight reduction up to 16.8% in the 12 mg group using the efficacy estimand^{[5 ]}. Detailed results were expected to be presented at a medical meeting and published later; until peer review, these data should be interpreted as topline sponsor-reported findings.

Where the evidence stands

Overall, retatrutide has stronger evidence than many “research peptides” discussed online because it has peer-reviewed phase 1 and phase 2 data and phase 3 topline readouts. However, it remains investigational. The major unresolved questions are long-term safety, tolerability, durability of weight loss, effect on lean mass and nutritional status, comparative benefit versus approved alternatives, and whether imaging or symptom outcomes translate into long-term clinical benefit.

Public discourse

Ania M. Jastreboff, MD, PhD, an obesity-medicine researcher and phase 2 trial investigator, emphasized that the phase 2 trial had not clearly reached a plateau by the end of treatment^{[8 ]}.

Ildiko Lingvay, MD, MPH, endocrinologist, in a Nature Medicine News & Views, framed retatrutide’s phase 2 data as part of a broader shift in obesity pharmacotherapy while emphasizing caution^{[12 ]}.

Kenneth Custer, PhD, executive vice president and president of Lilly Cardiometabolic Health, framed the TRIUMPH-4 knee osteoarthritis trial as relevant to people with obesity and mobility-limiting pain^{[11 ]}.

Jessica Duncan, MD, an obesity-medicine physician, described the mechanism in GQ and warned that retatrutide was not yet available through normal prescribing pathways^{[13 ]}.

Rozalina McCoy, MD, an endocrinologist and health-services researcher, warned about counterfeit or mislabeled online products and emphasized individualized clinical decision-making if retatrutide is eventually approved^{[14 ]}.

Public discourse reflects the views of the speakers cited and does not represent medical advice or the editorial position of ProPeptideGuide.

Side effects and safety

Because retatrutide is not approved, there is no finalized FDA label describing contraindications, boxed warnings, drug interactions, or postmarketing safety findings. Safety information comes from clinical trials, sponsor topline releases, and class-based concerns from incretin therapies.

Trial-reported adverse events

In the phase 2 obesity program, Lilly reported that gastrointestinal adverse events were the most common and were generally mild to moderate, often occurring during dose escalation^{[8 ]}. In TRANSCEND-T2D-1, Lilly reported nausea, diarrhea, and vomiting as the most common adverse events, with dysesthesia also reported in a minority of participants^{[5 ]}. In TRIUMPH-4, Lilly reported nausea, diarrhea, constipation, vomiting, decreased appetite, and dysesthesia; adverse-event discontinuation rates were higher in retatrutide groups than placebo and included discontinuations for perceived excessive weight loss^{[11 ]}.

Class-based and mechanistic concerns

Potential clinical concerns include dehydration, gallbladder disease, pancreatitis signals that require evaluation across the class, excessive weight loss, undernutrition, lean-mass loss, and tolerability limitations. Retatrutide’s glucagon receptor activity also raises theoretical questions about heart rate, energy expenditure, hepatic effects, and glucose dynamics that require full phase 3 and regulatory review^{[4 ]}.

The biggest current safety risk is online product

The greatest current safety risk for the public is not trial-supervised retatrutide; it is unapproved products sold online. FDA has warned that unapproved GLP-1 products do not undergo FDA review for safety, effectiveness, or quality, and that retatrutide cannot be used in compounding under federal law^{[3 ]}. Products marketed as “research use only” but sold with human-use claims or instructions may be counterfeit, contaminated, incorrectly dosed, or not retatrutide at all^{[3 ,6 ]}.

Long-term safety data are still incomplete. Until full phase 3 results are published and regulators review a complete application, retatrutide should be described as promising but investigational.

Available through

Retatrutide is not currently available through FDA-compliant prescribing or compounding channels in the United States. Lilly states that retatrutide is legally available only to participants in its clinical trials, and FDA states that retatrutide cannot be used in compounding under federal law^{[3 ,5 ]}.

ProPeptideGuide does not link to or endorse gray-market vendors, “research chemical” sellers, online peptide shops, or clinics advertising non-FDA-compliant retatrutide.